Study of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine Tumours - Related Studies

Study of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine Tumours

This study is currently recruiting participants.

Study NCT00353496. Last updated on October 21, 2008. Information provided by Ipsen

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Endocrine Tumors

2	Additional conditions recognized in this trial
		Adenoma, Islet Cell
		Endocrine Gland Neoplasms

3	More general conditions related to this trial
		Adenoma
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine System Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Pancreatic Diseases
		Pancreatic Neoplasms

4	Interventions listed in this trial
		lanreotide (Autogel formulation)
		Placebo

5	Additional drug interventions recognized in this trial
		Angiopeptin
		Lanreotide

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Cardiovascular Agents
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		Ipsen